TrialDiabetes, obesity & metabolism2019

Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.

Cees J Tack et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.